Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit. — GODIF  

Fluid Overload Clinical Trial

Official title: Goal Directed Fluid Removal With Furosemide in Intensive Care Patients With Fluid Overload - A Randomised, Blinded, Placebo-controlled Trial (GODIF).

Status Recruiting

Clinical Trial Summary

This study evaluates the benefits and harms of goal directed fluid removal with furosemide versus placebo in critical ill adult patients with fluid overload in the intensive care unit. Half of the patients will receive furosemide and the other half placebo. The treatment will continue until the excess fluid is excreted.

Clinical Trial Description

Fluid overload is a common and serious complication in patients admitted to the intensive care unit (ICU). A core element of therapy in the ICU is resuscitation with crystalloid solutions. In many cases fluid accumulate, and patients become fluid overloaded. Several observational studies indicate a detrimental effect of fluid overload in different clinical settings, including patients with acute kidney injury. It is unknown whether this association is causal or if the increased tendency to accumulate fluid is a marker of disease severity and thereby a higher risk of death. The investigators want to investigate this in critical ill patients with fluid overload of 5% or more by randomizing them to furosemide (diuretics) or placebo. ;

Related Conditions & MeSH terms

• Fluid Overload

• NCT number: NCT04180397
• Study type: Interventional
• Source: Nordsjaellands Hospital
• Contact: Sine Wichmann, MD
• Phone: +45 26142620
• Email: sine.wichmann@regionh.dk
• Status: Recruiting
• Phase: Phase 4
• Start date: August 17, 2020
• Completion date: June 17, 2025